About ManagedLab

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium dolemue launti totam aperiam, eaque ipsa quae abillo. Invente veriatis et quasi.

Agtech Startup GroGuru Gets Audience Kudos at EvoNexus Demo Day

Posted by |2019-06-06T14:42:04-07:00June 6th, 2019|

Three wildly different startups among those incubating at EvoNexus, a La Jolla, CA-based nonprofit organization that supports early-stage tech companies, earned top marks from the audience at a pitch contest this week. EvoNexus typically hosts a “Demo Day” event twice per year to highlight the top startups currently housed in its incubator. The event is […]

Immunovant Hires Salzmann Away From Eli Lilly for CEO Post

Posted by |2019-06-05T09:41:41-07:00June 5th, 2019|

Veteran Eli Lilly (NYSE: LLY) executive Pete Salzmann has been appointed CEO of Immunovant. Salzmann has spent 20 years at Lilly, most recently as global clinical development leader for baricitinib (Olumiant), the rheumatoid arthritis drug that won FDA approval last year. Immunovant, which splits its operations between New York and Basel, Switzerland, is a subsidiary […]

Eli Lilly’s Approved Migraine Drug Wins FDA OK for Cluster Headache

Posted by |2019-06-04T15:47:22-07:00June 4th, 2019|

An Eli Lilly migraine drug that was approved last fall now has the regulatory nod to treat a rarer form of headache that tends to occur in clusters. The FDA on Tuesday approved the Lilly (NYSE: LLY) drug galcanezumab (Emgality) for episodic cluster headaches, which patients experience as one to four headaches per day, each […]

Inhibrx, Fresh Off $40M Funding to Advance Cancer Drugs, Eyes IPO

Posted by |2019-06-03T19:51:41-07:00June 3rd, 2019|

Two weeks after raising $40 million to push ahead with its drug development programs, Inhibrx submitted paperwork to the SEC revealing that it aims to raise money in the public market, too. The La Jolla, CA-based company, which is developing protein drugs targeting cancer and other diseases, was founded in 2010. Read more about the […]

Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More

Posted by |2019-06-03T03:30:09-07:00May 31st, 2019|

[Corrected 5/31/19, 8:48 am ET. See below.] Pharmaceutical companies that make or market opioids have found themselves in legal hot water, and much of the heat is coming from Oklahoma. This week, a trial began litigating Johnson & Johnson’s responsibility for opioid addiction in the Sooner State. Johnson & Johnson (NYSE: JNJ) entered the Norman, […]

The Winners of the 2019 Xconomy Awards San Diego Are…

Posted by |2019-05-29T19:27:32-07:00May 29th, 2019|

The nominees and finalists for the first-ever Xconomy Awards San Diego were an impressive bunch, making it tough for our judges and the editors to pick the winners. There were multiple deserving companies and people in each category. After much discussion and debate, we decided that these winners represent the best of the San Diego […]

The Biotech IPO Queue Grows Longer as Five More Companies File

Posted by |2019-05-28T09:07:41-07:00May 28th, 2019|

The biotech IPO train is rolling onward, with five more companies climbing aboard. The companies, ranging from a late-stage firm looking to finance Phase 3 studies to preclinical companies laying the groundwork for their first drug trials with human subjects, submitted their paperwork to the SEC late Friday—just before the start of Memorial Day weekend. Here’s […]

Stoke Therapeutics Preps IPO to Bring Dravet Syndrome Drug to Clinic

Posted by |2019-05-28T03:30:08-07:00May 24th, 2019|

After Stoke Therapeutics closed $90 million in financing last fall, CEO Ed Kaye signaled his biotech would seek more cash through an IPO soon. The preclinical-stage biotech is now officially on a path to the public markets. In paperwork filed late Thursday with the SEC, Bedford, MA-based Stoke set a preliminary $86 million target for […]

Nektar Forms New Company Inheris to Take Reins on Pain, CNS Drugs

Posted by |2019-05-23T08:43:26-07:00May 23rd, 2019|

If Nektar Therapeutics wins FDA approval this summer for an opioid painkiller it designed to be less addictive than other opioids, another company will usher the new product onto the market. San Francisco-based Nektar (NASDAQ: NKTR) announced Thursday that it formed Inheris Biopharma to take the reins on pain drug NKTR-181, as well as several […]

Cala Health Secures $50M to Launch Anti-Tremor Wrist Device

Posted by |2019-05-22T15:40:37-07:00May 22nd, 2019|

Cala Health announced this week it raised $50 million in a Series C financing that will fund the market introduction of its wristwatch-like device that delivers nerve stimulation as a remedy for tremors of the hands. New investors Novartis, Baird Capital, LifeSci Venture Partners and TriVentures participated in the fundraising round, and were joined by […]

California Life Sciences Fueled by Education, Established Companies

Posted by |2019-05-21T17:47:59-07:00May 21st, 2019|

New medicines, devices, and diagnostics produced by the life sciences community in California are giving clinicians better tools to fight disease and improve quality of life for patients around the world. Emerging technologies, such as stem cell and gene therapies, are beginning to make their mark. According to the California Life Sciences Association (CLSA)’s latest […]

Voyager’s CSO Dinah Sah to Retire, Omar Khwaja Expands Role

Posted by |2019-05-20T15:15:26-07:00May 20th, 2019|

Dinah Sah is retiring from her position as chief scientific officer of Voyager Therapeutics (NASDAQ: VYGR). In her place, the Cambridge, MA-based gene therapy developer said that Chief Medical Officer Omar Khwaja will take on an expanded role as chief medical officer and head of research and development. The changes will happen June 28, but […]

Load More Posts